To put it in a nut shell, our paper elucidated that CERS6‐AS1 functions as a malignancy promoter in breast cancer by binding to IGF2BP3 to enhance the stability of CERS6 mRNA, implying that CERS6‐AS1 might serve as a molecular target for BC to improve prognosis. The gene discussed is IGF2BP3; the disease is breast carcinoma.